To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Apixiban more effective than enoxaparin for prevention of postoperative thromboembolism

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
March 2013

Apixiban more effective than enoxaparin for prevention of postoperative thromboembolism

Vol: 2| Issue: 2| Number:189| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial

Lancet. 2010 Mar 6;375(9717):807-15.

Contributing Authors:
MR Lassen GE Raskob A Gallus G Pineo D Chen P Hornick ADVANCE-2 investigatorsCollaborators (181)

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

3057 patients scheduled for an elective unilateral or same-day bilateral total knee replacement were randomized to the drug used in prevention of venous thromboembolism, either oral apixiban or subcutaneous enoxaparin. 60 days after the final dose apixiban when compared to enoxaparin was found to be more effective in preventing thrombosis events, had lesser bleeding risks, and had the convenience ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue